Shots:

• The US FDA has accepted the BLA under the 351(k) for CHS-201 (biosimilar, ranibizumab) with an anticipated BsUFA date is Aug 02, 2022
• If approved, the company plans to launch the Lucentis biosimilar in the US in H2'22
• Additionally, Coherus' biosimilar portfolio includes Udenyca which has launched in the US in Jan'19 while CHS-1420 (biosimilar, adalimumab) is currently under FDA's review with anticipated PDUFA date on Dec'21 & CHS-305 (biosimilar, bevacizumab) is currently being evaluated in PK study to support a BLA submission in 2022

to­ / article | Ref: Coherus | Image: Coherus